Iris Gorfinkel
YOU?
Author Swipe
View article: Attitudes, barriers, and facilitators to adherent completion of the recombinant zoster vaccine regimen in Canada: Qualitative interviews with healthcare providers and patients
Attitudes, barriers, and facilitators to adherent completion of the recombinant zoster vaccine regimen in Canada: Qualitative interviews with healthcare providers and patients Open
This qualitative, cross-sectional study aimed to understand the barriers and facilitators related to the adherence and completion of the recombinant zoster vaccine (RZV) two-dose series in Canada, as perceived by healthcare providers (HCPs…
View article: Cost-of-living challenges highlight urgency for clinicians to prescribe affordable medications
Cost-of-living challenges highlight urgency for clinicians to prescribe affordable medications Open
More than half of prescribers in the United States use real-time prescription benefit (RTPB) technology as an add-on to electronic health record (EHR) systems.[1][1] If such technology were adopted in Canada, it eventually may allow clinic…
View article: Long-term Protection Against Herpes Zoster by the Adjuvanted Recombinant Zoster Vaccine: Interim Efficacy, Immunogenicity, and Safety Results up to 10 Years After Initial Vaccination
Long-term Protection Against Herpes Zoster by the Adjuvanted Recombinant Zoster Vaccine: Interim Efficacy, Immunogenicity, and Safety Results up to 10 Years After Initial Vaccination Open
Approximately 10 years after vaccination with the recombinant zoster vaccine (RZV), an interim analysis of this follow-up study of the ZOE-50/70 trials demonstrated that efficacy against herpes zoster remained high. Moreover, the safety pr…
View article: The Adjuvanted Recombinant Zoster Vaccine Confers Long-Term Protection Against Herpes Zoster: Interim Results of an Extension Study of the Pivotal Phase 3 Clinical Trials ZOE-50 and ZOE-70
The Adjuvanted Recombinant Zoster Vaccine Confers Long-Term Protection Against Herpes Zoster: Interim Results of an Extension Study of the Pivotal Phase 3 Clinical Trials ZOE-50 and ZOE-70 Open
Background This ongoing follow-up study evaluated the persistence of efficacy and immune responses for 6 additional years in adults vaccinated with the glycoprotein E (gE)-based adjuvanted recombinant zoster vaccine (RZV) at age ≥50 years …
View article: The potential benefits of a national vaccine registry for Canada
The potential benefits of a national vaccine registry for Canada Open
The article by Duong about the vaccine rollout didn’t deal with a key deficiency in Canada’s vaccine strategy.[1][1] Canada continues to lack a centralized tracking system for SARS-CoV-2 vaccines. Instead, reliance is placed on a patchwork…
View article: Using bar codes to create a robust national vaccine registry
Using bar codes to create a robust national vaccine registry Open
I thank Dr. Hapuhennedige for the informative article published in CMAJ , “Vaccination debates may obscure access issues.”[1][1] Canada continues to lack a tracking system for adult vaccines. Instead, provinces and territorial public healt…
View article: Efficacy Results of a Trial of a Herpes Simplex Vaccine
Efficacy Results of a Trial of a Herpes Simplex Vaccine Open
Two previous studies of a herpes simplex virus type 2 (HSV-2) subunit vaccine containing glycoprotein D in HSV-discordant couples revealed 73% and 74% efficacy against genital disease in women who were negative for both HSV type 1 (HSV-1) …
View article: Engaging physicians to prescribe more cost-effectively: Blueprint for change.
Engaging physicians to prescribe more cost-effectively: Blueprint for change. Open
The cost of pharmaceutical spending in Canada continues to rise with concerning rapidity. In 2018 it was the fastest growing category of health care expenditures, at a rate of 3.2% per capita per year. Earlier estimates put total health ca…
View article: House calls: what doctors get when they give
House calls: what doctors get when they give Open
Iris Gorfinkel: I confess. Seeing my patient Jill in her home was something I’d been putting off for over a month. There are windows in life, particularly those with unwanted views, that are preferably not peered through too often. Jill’s …
View article: “You’re no longer safe to drive ...”
“You’re no longer safe to drive ...” Open
“Aging is a battlefield,” a stalwart 80-plus patient asserts as he leaves my general practice clinic. He is barely gone when a mother and daughter enter the room. I finish my progress note on the previous patient and look up to see another…
View article: 2779. Efficacy of the Adjuvanted Recombinant Zoster Vaccine According to Sex, Geographic Region, and Geographic Ancestry/Ethnicity: A Post-hoc Analysis
2779. Efficacy of the Adjuvanted Recombinant Zoster Vaccine According to Sex, Geographic Region, and Geographic Ancestry/Ethnicity: A Post-hoc Analysis Open
Background The risk of herpes zoster (HZ) has been reported to vary by sex and ethnicity. In 2 large-scale clinical trials, ZOE-50 (NCT01165177) and ZOE-70 (NCT01165229), the adjuvanted recombinant zoster vaccine (RZV) demonstrated high va…
View article: Efficacy of the adjuvanted recombinant zoster vaccine (RZV) by sex, geographic region, and geographic ancestry/ethnicity: A post-hoc analysis of the ZOE-50 and ZOE-70 randomized trials
Efficacy of the adjuvanted recombinant zoster vaccine (RZV) by sex, geographic region, and geographic ancestry/ethnicity: A post-hoc analysis of the ZOE-50 and ZOE-70 randomized trials Open
While the ZOE-50/70 studies were not powered or pre-designed for these post-hoc analyses, RZV appears efficacious against HZ and PHN irrespective of sex, region, or geographic ancestry/ethnicity.
View article: Medical conditions at enrollment do not impact efficacy and safety of the adjuvanted recombinant zoster vaccine: a pooled post-hoc analysis of two parallel randomized trials
Medical conditions at enrollment do not impact efficacy and safety of the adjuvanted recombinant zoster vaccine: a pooled post-hoc analysis of two parallel randomized trials Open
In two pivotal efficacy studies (ZOE-50; ZOE-70), the adjuvanted recombinant zoster vaccine (RZV) demonstrated >90% efficacy against herpes zoster (HZ).Adults aged ≥50 or ≥70 years (ZOE-50 [NCT01165177]; ZOE-70 [NCT01165229]) were randomiz…
View article: Enabling Patient Portals to Access Primary Care Medical Records: Maximizing Collaboration in Care Between Patients and Providers
Enabling Patient Portals to Access Primary Care Medical Records: Maximizing Collaboration in Care Between Patients and Providers Open
Portals to allow patients to access their primary care medical records are necessary to achieve true collaborative care between doctors and patients. In this article, we outline a practical approach to achieving this goal that involves Min…
View article: The quietly defiant patient
The quietly defiant patient Open
It is 11:30 pm on a chilly fall night. I am in the emergency department, barely a quarter of the way through my internship. I face a fatigued, bespectacled 50-something-year-old man who has waited a gruelling six and a half hours for this …
View article: A call to mandate patient access to personal primary care medical records across Canada
A call to mandate patient access to personal primary care medical records across Canada Open
KEY POINTS Eighty-five percent of family physicians use an electronic medical record.[1][1] Yet, despite this, clinicians other than the patients' family physicians still struggle to access medical information for patients they encounter. …
View article: Efficacy, Immunogenicity and Safety of adjuvanted Herpes Zoster-Virus Subunit Vaccine Candidates in Adults from 60 Years and older : Results from the Efficacy Studies ZOE-50 and ZOE-70
Efficacy, Immunogenicity and Safety of adjuvanted Herpes Zoster-Virus Subunit Vaccine Candidates in Adults from 60 Years and older : Results from the Efficacy Studies ZOE-50 and ZOE-70 Open
Efficacy, Immunogenicity and Safety of adjuvanted Herpes Zoster-Virus Subunit Vaccine Candidates in Adults from 60 Years and older: Results from the Efficacy Studies ZOE-50 and ZOE-70
View article: We need to mandate drug cost transparency on electronic medical records
We need to mandate drug cost transparency on electronic medical records Open
KEY POINTS Canada has the dubious distinction of boasting the second highest per capita drug costs in the world, after the United States, with prescription drugs as the second most costly component of health care.[1][1] Yet physicians have…
View article: Efficacy of the Herpes Zoster Subunit Vaccine in Adults 70 Years of Age or Older
Efficacy of the Herpes Zoster Subunit Vaccine in Adults 70 Years of Age or Older Open
In our trial, HZ/su was found to reduce the risks of herpes zoster and postherpetic neuralgia among adults 70 years of age or older. (Funded by GlaxoSmithKline Biologicals; ZOE-50 and ZOE-70 ClinicalTrials.gov numbers, NCT01165177 and NCT0…